公开(公告)号：AU2022201741A1

公开(公告)日：2022-04-07

申请号：AU2022201741

申请日：2022-03-14

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2019229398B2

公开(公告)日：2021-09-16

申请号：AU2019229398

申请日：2019-09-12

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CA3007788C

公开(公告)日：2020-03-10

申请号：CA3007788

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K39/395 ,  A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2019229398A1

公开(公告)日：2019-10-03

申请号：AU2019229398

申请日：2019-09-12

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：EA032463B1

公开(公告)日：2019-05-31

申请号：EA201490798

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: Описанакомбинация: а) необратимогоингибиторатирозинкиназыБрутона (Btk), причемнеобратимыйингибитортирозинкиназыБрутона (Btk) представляетсобой (R)-1-(3-(4-амино-3-(4-феноксифенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил)пиперидин-1-ил)проп-2-ен-1-он (PCI-32765/ибрутиниб); и b) GA 101; вкоторойнеобратимыйингибитор Btk и GA 101 находятсяв видераздельныхлекарственныхформ. Такжеописаноприменениеуказаннойкомбинациидляизготовлениялекарственногосредствадлялечениягематологическойзлокачественнойопухолиу субъекта, нуждающегосяв этом.

公开(公告)号：SG10201809111XA

公开(公告)日：2018-11-29

申请号：SG10201809111X

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. Fig. 1

公开(公告)号：AU2012325804B2

公开(公告)日：2017-09-07

申请号：AU2012325804

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.